News
KOD
3.620
+2.55%
0.090
Tracking Baker Brothers Portfolio - Q1 2025 Update
Seeking Alpha · 4d ago
Weekly Report: what happened at KOD last week (0609-0613)?
Weekly Report · 5d ago
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
NASDAQ · 06/13 15:30
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Seeking Alpha · 06/12 15:03
Weekly Report: what happened at KOD last week (0602-0606)?
Weekly Report · 06/09 11:33
Kodiak Sciences Holds 2025 Annual Stockholders Meeting
TipRanks · 06/03 21:08
Weekly Report: what happened at KOD last week (0526-0530)?
Weekly Report · 06/02 11:42
Weekly Report: what happened at KOD last week (0519-0523)?
Weekly Report · 05/26 11:41
Weekly Report: what happened at KOD last week (0512-0516)?
Weekly Report · 05/19 11:31
Cautious Hold Rating on Kodiak Sciences Amid Strategic Developments and Past Trial Challenges
TipRanks · 05/19 10:17
Kodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss
Dow Jones · 05/15 17:41
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 05/15 17:06
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Barchart · 05/15 11:20
Kodiak Sciences GAAP EPS of $1.09 beats by $1.99
Seeking Alpha · 05/14 21:28
Kodiak Sciences Q1 EPS $(1.09) Misses $(0.87) Estimate
Benzinga · 05/14 20:30
Kodiak Sciences reports Q1 EPS ($1.09), consensus (87c)
TipRanks · 05/14 20:22
KODIAK SCIENCES ANNOUNCES RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2025 FINANCIAL RESULTS
Reuters · 05/14 20:15
*Kodiak Sciences 1Q Loss/Shr $1.09 >KOD
Dow Jones · 05/14 20:15
Press Release: Kodiak Sciences Announces Recent -3-
Dow Jones · 05/14 20:15
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
Dow Jones · 05/14 20:15
More
Webull provides a variety of real-time KOD stock news. You can receive the latest news about Kodiak Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.